{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'Allow blood to clot at room temperature for at least 30 minutes while standing upright in a', 'rack.', 'Centrifuge tube within 8 hours of collection at 1100 to 1300 RCF(g) for 10 minutes.', 'Gently remove the vacutainer stopper avoiding serum contamination with red blood cells.', 'Using a single-use pipette, transfer 1.0 mL aliquots of serum (top layer) into 1.0mL or 1.8 mL', 'cryovials, up to 5 cryovials are expected. If less than 1 mL of processed serum is collected,', 'it is a protocol deviation', 'All cryovial aliquots will be barcode labelled and contain a unique identifier via REDCap.', 'Numbers should be placed lengthwise on the tube.', 'Freeze the cryovials at -80\u00b0C in the temperature-monitored research center freezer for', 'future shipment.', 'Serum aliquots will be stored in the Duke Human Vaccine Institute Accessioning Lab, the', 'Johns Hopkins Center for Immunization Research laboratory, and at CCHMC Schubert', 'Research Clinic Laboratory until planned HAI analyses at which point the samples stored at', 'JHU and Cincinnati will be shipped to Duke for planned laboratory analysis', '6', 'LABORATORY ANALYSES', '6.1 Baseline SARS-CoV-2 antibody', 'Serum samples obtained at the Visit 1 (prior to vaccination) will be assayed for the presence of', 'pre-existing SARS-CoV-2 antibody using the AdviseDx SARS-CoV-2 IgG Il assay and the', 'Alinitiy I SARS-CoV-2 IgG assay. The AdviseDx SARS-CoV-2 IgG II assay is a', 'chemiluminescent microparticle immunoassay intended for the qualitative and semi-quantitative', 'detection of IgG spike antibodies to SARS-CoV-2 in human serum. The Alinity I SARS-CoV-2', 'IgG assay is a chemiluminescent microparticle immunoassay intended for the qualitative', 'detection of nucleocapsid IgG antibodies to SARS-CoV-2 in human serum. All results will be', 'interpreted as either positive or negative. A positive result on any assay will be interpreted as a', 'positive antibody test result. The assays are intended for use as an aid in identifying individuals', 'with an adaptive immune response to SARS-CoV-2 indicating recent or prior infection. Both', \"assays are currently only for use under the FDA's Emergency Use Authorization.\", 'SARS-CoV-2 antibody assays will be performed in the Immunology Virology Quality', 'Assessment Center (IVQAC) at the DHVI. The IVQAC is a GCLP laboratory which is also', 'accredited by CAP, CLIA and ISO-17043.', '6.2 Influenza Hemagglutination Inhibition (HAI) Assay', 'Influenza Hemagglutination Inhibition (HAI) Assays will be performed on sera collected,', 'contingent on additional funding. Briefly, reference wild-type, reassortant, or vaccine virus', 'strains representative of the specific viral antigens included in the 2021-22 influenza vaccine will', 'be used to evaluate the relative levels of all four influenza strain-specific antibodies in', 'participant serum samples collected pre- and 21 or 28 days post-vaccination from all study', 'participants. To accomplish these activities, all participant samples will be interrogated for', 'influenza antibodies against the strains of interest using the influenza hemagglutination', 'inhibition assay (HI). This assay is considered the \"gold-standard\" measure by which to', 'evaluate seroconversion/seroprotection in response to seasonal influenza vaccination. This', 'assay will be performed in accordance with the Duke Regional Biocontainment Laboratory', \"Virology Unit's fully optimized and approved SOP (RVUSOP004 Influenza HI of Serum\", '45']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'Samples). Briefly, test samples will be assayed by HAI as duplicate 2-fold dilution series', 'starting at 1:10. Serum dilutions are then incubated with a concentration of virus verified to', 'possess a known potential for red blood cell (RBC) agglutination. The presence of virus-specific', 'antibodies is visualized via incubation of the virus-serum mixture with a RBC solution; the', 'endpoint titer for a given dilution series is then expressed as the reciprocal of the final dilution in', 'which complete HAI is observed. By convention, seronegative samples are defined as having', 'an endpoint HAI titer < 40 and seropositive samples as having an endpoint titer of >1:40; and', 'seroconversion as a 4-fold change in endpoint titer relative to pre-immunization baseline or a', 'change from <10 to 1:4040', '6.3 Future Studies', 'In addition to the specified analyses described thus far, there may be other tests or assays that', 'have yet to be identified that may be important for interpreting our study findings or of relevance', 'to co-administration of mRNA COVID-19 vaccines and IIV4 simultaneously. Additional', 'laboratory assays may test for antibodies against other bacteria or viruses, markers of', 'inflammation, or used in research assessing vaccine co-administration or health outcomes.', 'Specimens banked for use in other studies will be linked to information (including identifying', 'information) that participants provided to the study. Because it is unknown if future testing will', 'be of any utility, results of future testing will not be provided.', '7', 'STATISTICAL CONSIDERATIONS', \"In collaboration with Johns Hopkins University and Cincinnati Children's Hospital sites, the\", 'research team at Duke will oversee the statistical analysis. Data will reside on a secure Duke', 'server maintained by Duke Health Technology Solutions (DHTS). For the study, a database will', 'be developed and a data set for the study without personal identifiers will be made available to', 'the CDC upon request. Duke statisticians will develop a comprehensive Statistical Analysis', 'Plan. The summary points of the analysis plan are presented below.', '7.1 Analysis Plan', 'Should an interim safety analysis be required, the alpha level will be adjusted to assure the', 'overall type I error is maintained at the one-sided alpha 0.025 level for the primary outcome of', 'non-inferiority.', '7.1.1', 'Sample Size', 'Safety: Four reactogenicity events were included in the primary statistical endpoint: fever,', 'chills, myalgia, or arthralgia of moderate or greater severity. These were considered clinically', 'meaningful and were solicited in both mRNA COVID-19 vaccine trials. Headache and fatigue', 'were also solicited reactogencity in both trials, but each occurred at the moderate-severe grade', 'in >10% of participants after dose 1 placebo (in the Pfizer- Pfizer-BioNTech trial) and were', 'thought to be less specific13 Based on data from prelicensure studies 10,41,42 , we assume that', '15% of participants will have at least one reaction of moderate severity or greater to include', 'fever, chills, myalgia, or arthralgia reactogenicity event in the Sequential group. We have', 'selected a clinically meaningful noninferiority margin of 10%. We plan to recruit a total of 450', 'participants and assume a 5% drop out rate, leaving N=428 or N=214 per study group.', '46']\n\n###\n\n", "completion": "END"}